Astrazeneca starts Phase III trial for asthma drug
August 14, 2014 7:58 am
Astrazeneca (AZN.L) today announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma.
The trial will evaluate the safety and effectiveness of the new drug and comes just a day after the company reported positive results for the trial of its Gout treatment drug Lesinurad.
“We are pleased to begin the tralokinumab Phase III programme in severe asthma, further strengthening the breadth of our portfolio in respiratory disease, one of AstraZeneca’s core therapy areas,” said Bill Mezzanotte, Vice President and Head of Inflammation, Neuroscience and Respiratory in AstraZeneca’s Global Medicines Development unit. “Patients with severe asthma currently have limited treatment options and need more effective therapies to control their disease. The development of tralokinumab underscores our commitment to a personalised treatment approach for these patients, to improve their lives. Severe asthma is highly heterogeneous; we are working to better understand patient subtypes, identify potential biomarkers, and tailor therapies to cellular and molecular phenotypes to achieve the best clinical outcomes.”
Astrazeneca (AZN.L) today announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma.
The trial will evaluate the safety and effectiveness of the new drug and comes just a day after the company reported positive results for the trial of its Gout treatment drug Lesinurad.
“We are pleased to begin the tralokinumab Phase III programme in severe asthma, further strengthening the breadth of our portfolio in respiratory disease, one of AstraZeneca’s core therapy areas,” said Bill Mezzanotte, Vice President and Head of Inflammation, Neuroscience and Respiratory in AstraZeneca’s Global Medicines Development unit. “Patients with severe asthma currently have limited treatment options and need more effective therapies to control their disease. The development of tralokinumab underscores our commitment to a personalised treatment approach for these patients, to improve their lives. Severe asthma is highly heterogeneous; we are working to better understand patient subtypes, identify potential biomarkers, and tailor therapies to cellular and molecular phenotypes to achieve the best clinical outcomes.”
Related Posts: